Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

Feb. 11, 2025 1:41 PM ETRoyalty Pharma plc (RPRX) StockAI-Generated Earnings Calls Insights2 Comments
(6min)

Earnings Call Insights: Royalty Pharma (NASDAQ:RPRX) Q4 2024

Management View

  • Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this exceeded the initial guidance range of 5%-9%. For 2025, Portfolio
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

About RPRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RPRX--
Royalty Pharma plc